3Martin TR,Mathison JC,Tobias PS,et al.Lipopolysaccharide binding protein enhances the responsivenes of alveolar macrophages to bacterial lipopolysaccharide.Implications for cytokine production in normal and injured lungs[J].J Clin Invest,1992,90:2209-2219.
4Prieto A,Reyes E,Bemstein ED,et al.Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferon)[J].Am J Respir Crit Care Med,2001,163:1578-1583.
5Tzanakis N,Chrysofakis G,Tsoumakidou M,et al.Induced sputum CD8^+ T -lymphocyte subpopulations in chronic obstractive pulmonary disease[J].Respir Med,2004,98:57-65.
6Anthonisen NR,Manfreda J,Warren CPW,et al.Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.Ann Intern Med,1987,106(2):196-204.
7Celli BR,MacNee W,Agusti A,et al.Standards for diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23(6):932-946.
8Global Initiative for Chronic Obstructive Pulmonary Disease.Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease,Available at www.goldcopd.com,2006
9Davies L,Angus RM,Calverley PM.Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease:a prospective randomized controlled trial.Lancet,1999,354(9177):456-460.
10National Institute for Clinical Excellence(NICE).Chronic obstructive pulmonary disease.National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary case.Thorax,2004,59(Suppl 1):1-232.
